The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study
Joanne G Wildenbeest,Marie-Noëlle Billard,Roy P Zuurbier,Koos Korsten,Annefleur C Langedijk,Peter M van de Ven,Matthew D Snape,Simon B Drysdale,Andrew J Pollard,Hannah Robinson,Terho Heikkinen,Steve Cunningham,Thomas O'Neill,Bishoy Rizkalla,Ana Dacosta-Urbieta,Federico Martinón-Torres,Marlies A van Houten,Louis J Bont,RESCEU Investigators,Joanne Wildenbeest,Roy Zuurbier,Marlies van Houten,Annefleur Langedijk,Peter van de Ven,Louis Bont,Simon Drysdale,Joseph McGinley,Gu-Lung Lin,Matthew Snape,Andrew Pollard,Andrew Ives,Helen Wolfenden,Sanjay Salgia,Rohoth Shetty,Irene Rivero-Calle,Alberto Gómez-Carballa,Sara Pischedda,Carmen Rodriguez-Tenreiro,Harish Nair,Harry Campbell,Margaret Miller,Julie Baggott,Catherine Beveridge,Rachael McKernan,Philippe Beutels,Peter Openshaw,Adam Meijer,Thea Kølsen Fischer,Maarten van den Berge,Carlo Giaquinto,Michael Abram,Kena Swanson,Jeroen Aerssens,Charlotte Vernhes,Scott Gallichan,Veena Kumar,Eva Molero
DOI: https://doi.org/10.1016/S2213-2600(22)00414-3
Abstract:Background: Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available. Methods: We performed a multicentre, prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the health-care burden of RSV. The incidence of RSV-associated hospitalisations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically attended RSV infections. The study is registered with ClinicalTrials.gov, NCT03627572. Findings: In total, 9154 infants born between July 1, 2017, and April 1, 2020, were followed up during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV-associated hospitalisations in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight paediatric intensive care unit admissions, corresponding to 5·5% of 145 RSV-associated hospitalisations and 0·09% of the total cohort. Incidence of RSV infection in the active surveillance cohort confirmed by any diagnostic assay was 26·2% (24·0-28·6) and that of medically attended RSV infection was 14·1% (12·3-16·0). Interpretation: RSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalisation of one in every 56 healthy term-born infants in high-income settings. Immunisation of pregnant women or healthy term-born infants during their first winter season could have a major effect on the health-care burden caused by RSV infections. Funding: Innovative Medicines Initiative 2 Joint Undertaking, with support from the EU's Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations.